Scholar Rock to Participate in Upcoming Investor Conferences
August 29 2024 - 8:00AM
Business Wire
Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical
company focused on advancing innovative treatments for spinal
muscular atrophy (SMA), cardiometabolic disorders, and other
serious diseases where protein growth factors play a fundamental
role, today announced that management will participate in the
following upcoming investor conferences in September:
- Morgan Stanley 22nd Annual Global Healthcare Conference:
Scholar Rock is scheduled to participate in a fireside chat at 7:00
a.m. ET on Thursday, September 5 in New York City.
- 2024 Wells Fargo Healthcare Conference: Scholar Rock management
will participate in 1x1 meetings on Thursday, September 5 in
Boston.
A live webcast of the Morgan Stanley event may be accessed by
visiting the Investors & Media section of the Scholar Rock
website at http://investors.scholarrock.com. An archived replay of
the webcast will be available on the Company’s website for
approximately 90 days.
About Scholar Rock
Scholar Rock is a biopharmaceutical company that discovers,
develops, and delivers life-changing therapies for people with
serious diseases that have high unmet need. As a global leader in
the biology of the transforming growth factor beta (TGFβ)
superfamily of cell proteins and named for the visual resemblance
of a scholar rock to protein structures, the clinical-stage company
is focused on advancing innovative treatments where protein growth
factors are fundamental. Over the past decade, Scholar Rock has
created a pipeline with the potential to advance the standard of
care for neuromuscular disease, cardiometabolic disorders, cancer,
and other conditions where growth factor-targeted drugs can play a
transformational role.
Scholar Rock is the only company to show clinical
proof-of-concept for a muscle-targeted treatment in spinal muscular
atrophy (SMA). This commitment to unlocking fundamentally different
therapeutic approaches is powered by broad application of a
proprietary platform, which has developed novel monoclonal
antibodies to modulate protein growth factors with extraordinary
selectivity. By harnessing cutting-edge science in disease spaces
that are historically under-addressed through traditional
therapies, Scholar Rock works every day to create new possibilities
for patients. Learn more about our approach at ScholarRock.com and
follow @ScholarRock and on LinkedIn.
Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our
investors and the public using our company website
www.scholarrock.com, including, but not limited to, company
disclosures, investor presentations and FAQs, Securities and
Exchange Commission filings, press releases, public conference call
transcripts and webcast transcripts, as well as on Twitter and
LinkedIn. The information that we post on our website or on Twitter
or LinkedIn could be deemed to be material information. As a
result, we encourage investors, the media and others interested to
review the information that we post there on a regular basis. The
contents of our website or social media shall not be deemed
incorporated by reference in any filing under the Securities Act of
1933, as amended.
Scholar Rock® is a registered trademark of Scholar Rock,
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240829227012/en/
Scholar Rock: Investors Rushmie Nofsinger Scholar Rock
rnofsinger@scholarrock.com ir@scholarrock.com 857-259-5573
Media Molly MacLeod Scholar Rock mmacleod@scholarrock.com
media@scholarrock.com 802-579-599
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Nov 2024 to Dec 2024
Scholar Rock (NASDAQ:SRRK)
Historical Stock Chart
From Dec 2023 to Dec 2024